Ribeiro Luis, Ind Philip W
Imperial College London Institute of Clinical Sciences, National Heart and Lung Institute, London, UK.
Respiratory Medicine, Hammersmith Hospital, London, UK.
Breathe (Sheff). 2018 Sep;14(3):196-205. doi: 10.1183/20734735.020418.
Increasing cannabis use and legalisation highlights the paucity of data we have on the safety of cannabis smoking for respiratory health. Unfortunately, concurrent use of tobacco among marijuana smokers makes it difficult to untangle individual effect of marijuana smoking. Chronic cannabis only smoking has been shown in large cohort studies to reduce forced expiratory volume in 1 s/forced vital capacity increasing forced vital capacity in chronic use contrary to the picture seen in tobacco smoking. The cause of this is unclear and there are various proposed mechanisms including respiratory muscle training secondary to method of inhalation and acute anti-inflammatory effect and bronchodilation of cannabis on the airways. While cannabis smoke has been shown to increase symptoms of chronic bronchitis, it has not been definitively shown to be associated with shortness of breath or irreversible airway changes. The evidence surrounding the development of lung cancer is less clear; however, preliminary evidence does not suggest association. Bullous lung disease associated with marijuana use has long been observed in clinical practice but published evidence is limited to a total of 57 published cases and only one cross-sectional study looking at radiological changes among chronic users which did not report any increase in macroscopic emphysema. More studies are required to elucidate these missing points to further guide risk stratification, clinical diagnosis and management.
Cannabis smoking has increased and is likely to increase further with relaxation of legalisation and medicinal use of cannabinoids.Chronic marijuana smoking often produces symptoms similar to those of chronic tobacco smoking such as cough, sputum production, shortness of breath and wheeze.Cessation of marijuana smoking is associated with a reduction in respiratory symptoms and no increased risk of chronic bronchitis.Spirometry changes seen in chronic marijuana smokers appear to differ from those in chronic tobacco smokers. In chronic marijuana smokers there is an increase in FVC as opposed to a definite decrease in FEV.Multiple case series have demonstrated peripheral bullae in marijuana smokers, but no observational studies have elucidated the risk.There is currently no clear association between cannabis smoking and lung cancer, although the research is currently limited.
To update readers on legalisation of recreational and medicinal cannabis.To summarise the evidence base surrounding the respiratory effects of inhaled marijuana use.To provide clinicians with an understanding of the main differences between cannabis and tobacco to be able to apply this to patient education.To highlight common respiratory problems among cannabis users and the need for recreational drug history taking.
大麻使用的增加和合法化凸显了我们在大麻吸食对呼吸健康安全性方面数据的匮乏。不幸的是,大麻吸食者中同时使用烟草的情况使得难以厘清大麻吸食的个体影响。大型队列研究表明,长期仅吸食大麻会降低1秒用力呼气容积/用力肺活量,与吸烟情况相反,长期使用大麻会增加用力肺活量。其原因尚不清楚,有多种提出的机制,包括吸入方式导致的呼吸肌训练以及大麻对气道的急性抗炎作用和支气管扩张。虽然大麻烟雾已被证明会增加慢性支气管炎症状,但尚未明确显示其与呼吸急促或不可逆气道改变有关。关于肺癌发生的证据不太明确;然而,初步证据并未表明存在关联。在临床实践中,长期观察到与大麻使用相关的大疱性肺病,但已发表的证据仅限于总共57例已发表病例,且仅有一项横断面研究观察慢性使用者的放射学变化,该研究未报告任何宏观肺气肿增加情况。需要更多研究来阐明这些缺失点,以进一步指导风险分层、临床诊断和管理。
随着大麻合法化和医用大麻使用的放宽,大麻吸食有所增加且可能进一步增加。长期吸食大麻通常会产生与长期吸烟类似的症状,如咳嗽、咳痰、呼吸急促和喘息。停止吸食大麻与呼吸症状减轻以及慢性支气管炎风险增加无关。长期大麻吸食者的肺功能测定变化似乎与长期烟草吸食者不同。在长期大麻吸食者中,用力肺活量增加,而1秒用力呼气容积则明确降低。多个病例系列已证明大麻吸食者存在外周大疱,但尚无观察性研究阐明风险。目前,尽管研究有限,但大麻吸食与肺癌之间尚无明确关联。
向读者介绍娱乐性和医用大麻合法化情况。总结吸入大麻使用对呼吸影响的证据基础。使临床医生了解大麻和烟草之间的主要差异,以便能够将其应用于患者教育。强调大麻使用者中常见的呼吸问题以及获取娱乐性药物使用史的必要性。